XML 14 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventory
9 Months Ended
Sep. 30, 2013
Inventory
(4) Inventory

After approval of Vascepa on July 26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories consist of the following at September 30, 2013 and December 31, 2012 (in thousands):

 

     September 30, 2013      December 31, 2012  

Raw materials

   $ 4,993       $ 5,465   

Work in process

     12,166         15,471   

Finished goods

     9,283         326   

Finished goods inventory held by others

     641         —    
  

 

 

    

 

 

 
   $ 27,083       $ 21,262   
  

 

 

    

 

 

 

Inventory is valued at lower of cost or market value. During the three months ended September 30, 2013, the Company recorded an inventory reserve of $1.8 million related to certain inventories that are not recoverable in their current form. The materials are currently under investigation by the supplier and the Company. The reserve was recorded within research and development expense in the statement of operations as this supplier has yet to produce material qualified for commercial sale.